Efeito da dapagliflozina sobre a mortalidade em pacientes com insuficiência cardíaca: uma revisão integrativa da literatura
DOI:
https://doi.org/10.34119/bjhrv8n4-011Keywords:
insuficiência, coração, SGLT2, dapagliflozina, sintomasAbstract
A dapagliflozina, originalmente desenvolvida como um antidiabético oral, tem demonstrado benefícios significativos no manejo da insuficiência cardíaca (IC), independentemente da presença de diabetes mellitus tipo 2. Esta revisão integrativa teve como objetivo analisar a literatura recente sobre os efeitos da dapagliflozina na mortalidade de pacientes com IC. Foram incluídos 31 estudos, entre ensaios clínicos randomizados, metanálises e estudos observacionais. Os resultados mostraram redução consistente na mortalidade cardiovascular e nas hospitalizações por IC, além de melhora funcional e sintomática. Evidências indicam benefícios mesmo em subgrupos complexos, como idosos, pacientes com fração de ejeção preservada e indivíduos com múltiplas comorbidades. Apesar da eficácia comprovada, barreiras institucionais e lacunas no conhecimento médico limitam a implementação ampla da terapia, especialmente em contextos de baixa renda. Conclui-se que a dapagliflozina representa uma das mais promissoras intervenções farmacológicas atuais no tratamento da IC, sendo essencial sua integração à prática clínica com base em diretrizes e políticas públicas eficazes.
References
ADAMSON, C. et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, v. 43, p. 4406–4417, 2022. Disponível em: https://academic.oup.com/eurheartj/article/43/41/4406/6674666.
BERG, D. D. et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, v. 6, n. 5, p. 499–507, 2021. Disponível em: https://jamanetwork.com/journals/jamacardio/fullarticle/10.1001/jamacardio.2020.7585.
BUTT, J. H. et al. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. Journal of the American College of Cardiology, v.11, n.4, p.375-388, 2023. Disponível em: https://doi.org/10.1016/j.jchf.2022.11.014.
BUTT, J. H. et al. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation, 146:1210–1224, 2022. Disponível em: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061754.
BUTT, J. H. et al. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23, 601–613, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33594755/.
BUTT, J. H. et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide. Circulation: Heart Failure, v. 14, e008837, p. 1305–1318, 2021. Disponível em: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.121.008837.
BUTT, J. H. et al. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, v. 6, n. 6, p. 678–689, 2021. Disponível em: https://jamanetwork.com/journals/jamacardio/fullarticle/10.1001/jamacardio.2021.0379.
DESAI, A. S. et al. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction. JAMA Cardiology, v. 7, n. 12, p. 1227–1234, 2022. Disponível em: https://jamanetwork.com/journals/jamacardio/fullarticle/10.1001/jamacardio.2022.3736.
DOCHERTY, K. F. et al. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC: Asia, v. 2, n. 2, p. 139–153, 2023. Disponível em: https://doi.org/10.1016/j.jacasi.2022.02.004.
DOCHERTY, K. F. et al. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure, v. 10, n. 1, p. 52–64, 2022. Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006.
DOCHERTY, K. F. et al. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, v. 6, n. 11, p. 1298–1305, 2021. Disponível em: https://jamanetwork.com/journals/jamacardio/fullarticle/10.1001/jamacardio.2021.2632.
EMARA, A. N. et al. The clinical outcomes of dapagliflozin in patients with acute heart failure: A randomized controlled trial (DAPA-RESPONSE-AHF). European Journal of Pharmacology, v. 961, p. 176179, 2023. Disponível em: https://doi.org/10.1016/j.ejphar.2023.176179.
INZUCCHI, S. E. et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER). The Lancet Diabetes & Endocrinology, v. 10, n. 12, p. 869–881, 2022. Disponível em: https://doi.org/10.1016/S2213-8587(22)00308-4.
JHUND, P. S. et al. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology, v. 8, n. 6, p. 554–563, 2023. Disponível em: https://jamanetwork.com/journals/jamacardio/fullarticle/10.1001/jamacardio.2023.0711.
JHUND, P. S.; PONIKOWSKI, P. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, v. 143, p. 1962–1972, 2021. Disponível em: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.053659.
KONDO, T. et al. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal of the American College of Cardiology, v. 82, n. 10, 2023. Disponível em: https://doi.org/10.1016/j.jacc.2023.05.056.
KONDO, T. et al. Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation, v. 147, p. 1067–1078, 2023. Disponível em: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062918.
LORIA, F. et al. The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better. Cardiovascular Diabetology, v. 23, n. 423, 2024. Disponível em: https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02515-5.
MARTINEZ, F. A. et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, v. 141, p. 100–111, 2020. Disponível em: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.044133.
NASSIF, M. E. et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, v. 27, p. 1954–1960, 2021. Disponível em: https://doi.org/10.1038/s41591-021-01536-x. Acesso em: 25 jun. 2025.
OSTROMINSKI, J. W. et al. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. European Journal of Heart Failure, v. 24, p. 1892–1901, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36054231/.
PABON, M. et al. Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial. European Journal of Heart Failure, v. 25, p. 1663–1670, 2023. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3001.
PEIKERT, A. et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circulation: Heart Failure, v. 15, e010080, p. 934–943, 2022. Disponível em: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.010080.
PETRIE, M. C. et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA, v. 323, n. 14, p. 1353–1368, 2021. Disponível em: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.1906.
RODRIGUES, J. A. Avaliação Do Uso De Inibidores Do Cotransportador De Sódio E Glicose Tipo 2 (Isglt2) Em Pacientes Com Insuficiência Cardíaca Do Hospital Do Servidor Público Municipal De São Paulo. São Paulo: Hospital do Servidor Público Municipal, 2024.
ROSSI NETO, J. M. Dapaglifozina na Insuficiência Cardíaca com Fração de Ejeção Levemente Reduzida ou Preservada - DELIVER. Revista da Sociedade de Cardiologia do Estado de São Paulo, v. 34, n. 1, p. 15–19, 2024. Disponível em: http://dx.doi.org/10.29381/0103-8559/2024340115-9.
SOLOMON, S. D. et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine, v. 387, n. 12, p. 1089–1098, 2022. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2206286.
VADUGANATHAN, M. et al. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure. Journal of the American College of Cardiology, v. 80, n. 19, p. 1775–1784, 2022. Disponível em: https://doi.org/10.1016/j.jacc.2022.08.745.
VANDERNY, O. et al. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, v. 28, p. 2504–2511, 2022. Disponível em: https://doi.org/10.1038/s41591-022-02102-9.
WANG, X. et al. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure. Circulation, v. 14, p. 624–634, 2023. Disponível em: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.122.062832.
